OliX Pharmaceuticals, Inc (226950.KQ) Stock
OliX Pharmaceuticals, Inc

Company profile
OliX Pharmaceuticals reported revenue of 5.68 billion KRW for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 6.25 billion KRW. In Q2 2025 it reported a net loss of 9.20 billion KRW, against a net loss of 9.58 billion KRW a year earlier. Our analysis of its filings shows revenue shrinking from 9.32 billion KRW in fiscal year 2022 to 5.68 billion KRW in fiscal year 2024, 22.0% a year on average. OliX Pharmaceuticals reports about 81 full-time employees.
What stands out
- Revenue fell 66.7% in fiscal year 2024, from 17.06 billion KRW in fiscal year 2023, after a rise of 83.1% the year before.
- It reported a net loss in each of its last 5 fiscal years; the loss widened from 19.10 billion KRW in fiscal year 2023 to 40.66 billion KRW in fiscal year 2024.
- Its net profit margin over the last four reported quarters was -102.9%, against a median of 7.4% for 6 listed companies of similar size in its industry.
- Revenue turned up in Q2 2025: up 35.9% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2024.
About OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Largest shareholders
- Dong-Gi Lee15.81 %15.81%
- National Pension Service of Korea5.33%
- Kiwoom Investment Co., Ltd.2.40%
- Chung-Gil Kang0.2967 %0.30%
- Sin-Young Park0.095 %0.10%
Share of the company, as of September 25, 2026
Leadership
- Dong-Ki Lee Ph.D. — CEO & Director, 53
- Chunggil Kang — President of Management Dept, 54
- Jin Kim Young — MD & CFO
- Young Hye Baek — Vice President of IP & Legal Affairs
- Joonhyun Park — Managing Director & Head of Research
In the news
- OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund
- Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
- OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease
- OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention
How much revenue does OliX Pharmaceuticals make?
OliX Pharmaceuticals reported 5.68 billion KRW in revenue for fiscal year 2024, down 66.7% from 17.06 billion KRW in fiscal year 2023. In Q2 2025 revenue was 6.25 billion KRW.
What companies are similar to OliX Pharmaceuticals?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include LigaChem Biosciences Inc. (141080.KQ), Hugel, Inc. (145020.KQ), Celltrion Pharm, Inc. (068760.KQ), GC Biopharma Corp. (006280.KS).
How has OliX Pharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 2.47 billion KRW; FY2021, 3.67 billion KRW; FY2022, 9.32 billion KRW; FY2023, 17.06 billion KRW; FY2024, 5.68 billion KRW.
Has OliX Pharmaceuticals made a profit in recent years?
Net income by fiscal year: FY2020, a loss of 19.38 billion KRW; FY2021, a loss of 29.71 billion KRW; FY2022, a loss of 19.50 billion KRW; FY2023, a loss of 19.10 billion KRW; FY2024, a loss of 40.66 billion KRW. It reported a net loss in each of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “OliX Pharmaceuticals, Inc (226950.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/226950.KQ